Nappo G, Galvanin J, Gentile D, Capretti G, Pulvirenti A, Bozzarelli S, Rimassa L, Spaggiari P, Carrara S, Petitti T, Gavazzi F, Zerbi A
Pancreatic Surgery Unit, Humanitas Clinical and Research Center - IRCCS, Milan, Italy.
Pancreatic Surgery Unit, Humanitas Clinical and Research Center - IRCCS, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Pancreatology. 2021 Aug;21(5):950-956. doi: 10.1016/j.pan.2021.03.005. Epub 2021 Mar 18.
Ampullary carcinoma (AC) is histologically classified as intestinal (In-AC), pancreaticobiliary (Pb-AC) or mixed-AC. The prognostic role of AC subtypes has been debated and remains unclear. The aims of this study were to evaluate outcomes after pancreatoduodenectomy (PD) for each subtype of AC and to compare these with pancreatic ductal adenocarcinoma [PDAC] and distal cholangiocarcinoma [DCC].
PDs performed for AC between 2010 and 2018 were retrospectively evaluated. Histological subtype was obtained for all patients. One-year, 3-year and 5-year disease-free-survival (DFS) and overall survival (OS) rates were calculated. Kaplan-Meier survival analysis was performed to compare Pb-AC, In-AC and mixed-AC. Comparison with PDs performed for PDAC and DCC during the same period was also performed.
A total of 97 patients undergoing PD for AC were evaluated: 34 (35.1%) In-AC, 54 (55.7%) Pb-AC and 9 mixed-AC (9.3%). DFS and OS rates for Pb-AC were significantly lower compared to In-AC (p < 0.05 and p < 0.01), but similar to mixed-AC (p = 0.3 and p = 0.4). Adjuvant therapy was not associated with increased survival, regardless of the histological subtype (p > 0.05). During the same period, 337 and 53 PDs for PDAC and DCC, respectively, were performed. In-AC was associated with significantly better outcomes compared to PDAC and DCC (p < 0.001); DFS and OS rates for Pb-AC and mixed AC were significantly higher compared to PDAC (p < 0.001), but similar to DCC (p > 0.05).
Pb-AC has significantly worse survival compared to In-AC. Moreover, mixed-AC should be considered as Pb-AC. Pb-AC and mixed-AC seem to have better prognosis compared to PDAC, but similar to DCC.
壶腹癌(AC)在组织学上分为肠型(In-AC)、胰胆管型(Pb-AC)或混合型(mixed-AC)。AC各亚型的预后作用一直存在争议且仍不明确。本研究的目的是评估胰十二指肠切除术(PD)治疗各亚型AC后的结局,并将其与胰腺导管腺癌[PDAC]和远端胆管癌[DCC]进行比较。
对2010年至2018年间因AC行PD的患者进行回顾性评估。获取所有患者的组织学亚型。计算1年、3年和5年无病生存率(DFS)和总生存率(OS)。进行Kaplan-Meier生存分析以比较Pb-AC、In-AC和混合型AC。还与同期因PDAC和DCC行PD的患者进行了比较。
共评估了97例因AC行PD的患者:34例(35.1%)为In-AC,54例(55.7%)为Pb-AC,9例(9.3%)为混合型AC。与In-AC相比,Pb-AC的DFS和OS率显著更低(p<0.05和p<0.01),但与混合型AC相似(p=0.3和p=0.4)。无论组织学亚型如何,辅助治疗均与生存率提高无关(p>0.05)。同期,分别对337例PDAC和53例DCC患者行了PD。与PDAC和DCC相比,In-AC的结局显著更好(p<0.001);Pb-AC和混合型AC的DFS和OS率与PDAC相比显著更高(p<0.001),但与DCC相似(p>0.05)。
与In-AC相比,Pb-AC的生存率显著更差。此外,混合型AC应视为Pb-AC。与PDAC相比,Pb-AC和混合型AC似乎预后更好,但与DCC相似。